The limitations of the current oncolytic adenoviruses for cancer therapy include insufficient potency and poor distribution of the virus throughout the tumor mass. To address these problems, we generated an oncolytic adenovirus expressing the hyperfusogenic form of the gibbon-ape leukemia virus (GALV) envelope glycoprotein under the control of the adenovirus major late promoter. The oncolytic properties of the new fusogenic adenovirus, ICOVIR16, were analyzed both in vitro and in vivo, and compared with that of its non-fusogenic counterpart, ICOVIR15. Our results indicate that GALV expression by ICOVIR16 induced extensive syncytia formation and enhanced tumor cell killing in a variety of tumor cell types. When injected intratumorally or intravenously into mice with large pre-established melanoma or pancreatic tumors, ICOVIR16 rapidly reduced tumor burden, and in some cases, resulted in complete eradication of the tumors. Importantly, GALV expression induced tumor cell fusion in vivo and enhanced the spreading of the virus throughout the tumor. Taken together, these results indicate that GALV expression can improve the antitumoral potency of an oncolytic adenovirus and suggest that ICOVIR16 is a promising candidate for clinical evaluation in patients with cancer.
INTRODUCTION
Oncolytic adenoviruses represent promising anticancer agents. These vectors can be programmed to specifically target, replicate in and destroy cancer cells, whereas sparing normal cells. Progeny virions can spread throughout the tumor to infect adjacent or distant tumor cells, thereby amplifying the initial virus and potentially inducing tumor regression. 1 The feasibility and safety of oncolytic adenoviruses in human patients have been demonstrated in clinical trials with multiple modes of delivery, and the combination with standard chemotherapy or radiotherapy has the potential to further increase the antitumor activity of oncolytic adenoviruses. 2, 3 However, a significant therapeutic effect has not been clearly demonstrated to date. Therefore, improvements in the efficacy of oncolytic adenoviruses are required to obtain clear benefits in cancer patients.
Several encouraging strategies have been described to enhance the efficacy of oncolytic adenoviruses. These include engineering viral genes to increase virus release and spread, 4 combining the virus with other standard or experimental treatments, 5 --8 or arming adenoviruses with therapeutic transgenes. 9 The insertion of transgenes in the viruses can overcome some of their limitations and/or provide additional therapeutic benefits, separate to the properties of the virus itself. In this regard, enzymes like relaxin or hyaluronidase have been used to disrupt the extracellular matrix and enhance adenovirus spread; 10 --12 immune response-modifying genes have been used to stimulate an immune response against the tumor, 13 --16 and prodrug-activating enzymes with bystander effect have been used to increase the cytotoxicity of oncolytic adenoviruses. 17 --19 Expression of viral fusogenic membrane glycoproteins induces tumor cell killing with bystander effect through the induction of cell --cell fusion and massive syncytia formation. 20 In addition, the formation and subsequent disintegration of the syncytia is highly immunostimulatory and has the potential to induce strong systemic bystander effect. 21, 22 Various fusogenic membrane glycoproteins have been evaluated as a means to increase the potency of oncolytic viruses. 23 --25 Expression of the HIV gp120 fusogenic membrane glycoprotein by a replication-competent adenovirus enhanced virus release and facilitated dispersion of virus particles through a culture of HeLa --CD4 þ cells. 26 In a different strategy, coinjection of plasmid DNA encoding the gibbon-ape leukemia virus (GALV) envelope glycoprotein significantly enhanced the antitumor efficacy of the adenovirus therapy. 27 In addition, we have recently demonstrated that expression of the hyperfusogenic-form of the GALV by a replication-competent adenovirus enhanced tumor cell killing. 28 The replication-competent fusogenic adenovirus AdwtRGD --GALV killed cells through both viral replication and fusion of cells into large multinucleated syncytia.
Among the different viral fusogenic membrane glycoprotein, GALV is especially interesting because it is highly cytotoxic for tumor cells and is able to induce membrane fusion at neutral pH. However, arming oncolytic adenovirus with the GALV glycoprotein is challenging for two main reasons. First, GALV expression is highly toxic for adenovirus producer cells, making generation of high-titer adenoviral vectors difficult. In our previous report, we solved this toxicity by expressing GALV under the control of the major late promoter. 28 GALV expression during the late stage of viral replication was compatible with the virus replication, and the fusogenic virus could be obtained at high titers. Second, the insertion of the GALV gene (2004 bp) into the adenovirus genome is difficult to combine with other modifications required to obtain tumor selectivity, as it raises the genome size above the packaging limit.
In this report, we describe the insertion of the GALV gene into the genome of ICOVIR15, a potent oncolytic adenovirus, for which replication is restricted to cancer cells with a disrupted Rb pathway. 29 In ICOVIR15, selectivity is achieved by insertion of four palindromic E2F-binding sites and one Sp1-binding site in the E1a endogenous promoter. These modifications represent only an insertion of 151 bp, and therefore, they allow the accommodation of the GALV gene without impairing the viral functions. Using the new fusogenic oncolytic adenovirus, ICOVIR16, we sought to determine whether GALV expression would enhance the therapeutic potential of an oncolytic adenovirus in vivo. Virus distribution and antitumor activity of ICOVIR16 were analyzed using two different tumor models following intratumoral or systemic administration. We found that syncytia formation enhanced the intratumoral spread of oncolytic adenovirus and greatly improved its antitumor efficacy. We propose that ICOVIR16 is a promising candidate for clinical evaluation in patients with cancer.
RESULTS
Generation and characterization of ICOVIR16, an oncolytic adenovirus expressing GALV To generate an oncolytic adenovirus expressing GALV (ICOVIR16), we inserted the GALV gene into the ICOVIR15 genome ( Figure 1a) . As an oncolytic adenovirus, we chose ICOVIR15, as it displays an appealing efficacy/toxicity ratio with a genomic size that only exceeds the native Ad5 genome size by 151 bp. 29 Selectivity in ICOVIR15 was achieved by the insertion of eight E2F-binding sites and one Sp1-binding site in the E1a endogenous promoter. To restrict GALV expression to the later phases of the viral life cycle, GALV was inserted downstream of the fiber gene under the control of the major late promoter, using the splicing acceptor signal from the adenovirus IIIa gene and the Kozak consensus sequence before the GALV open-reading frame. Although the final genome size of ICOVIR16 is very close to the packaging limit size (B2.2 kb larger than Adwt genome), we decided not to delete any viral function to prevent a potential decrease in the oncolytic potency.
One concern regarding the large genome of ICOVIR16 was that this could result in genome instability and/or impaired virus production. To address this, ICOVIR15 and ICOVIR16 were plaque purified, amplified over multiple passages in A549 cells and purified on cesium chloride gradients. Restriction digestion analysis of the ICOVIR16 genome indicated that its genome was stable (data not shown). Moreover, the E1A promoter region and the GALV gene were sequenced and were confirmed to have the expected sequence. Of note, the physical and functional titers of the ICOVIR16-purified stock were comparable to that of ICOVIR15, and therefore, both ICOVIR15 and ICOVIR16 had a similar virus particle to transducing unit (TU) ratio (21.3 and 24.5, respectively), indicating that the increase in the genome size was not impairing the virus production. Moreover, virus titration by an a-hexon method in 293 cells indicated that most of 293 cells infected with ICOVIR16 formed syncytia (Figure 1b) .
To further confirm that GALV expression did not interfere with virus replication, A549 cells were infected at 25 multiplicity of infection (MOI) with ICOVIR15 and ICOVIR16. Cell extracts and supernatants (SNs) were harvested on day 2 and 3 after infection, and titered using an a-hexon staining protocol. As expected, GALV expression did not affect the virus life cycle or the virus yield. At day 3 post-infection, the level of ICOVIR16 replication (2633±675 TU per cell) was similar to that of ICOVIR15 (2650 ± 606 TU per cell). Furthermore, the amount of ICOVIR16 (737 ± 648 TU per cell) released into the medium was similar to that of ICOVIR15 (745±180 TU per cell).
Next, we determined the syncytia-forming ability of ICOVIR16 in tumor cells. Tumor cells were infected with ICOVIR15 and ICOVIR16 at a MOI of 0.05 (A549 cells and NP18 cells) or at an MOI of 0.1 (SKMel-28 cells), or were left uninfected. At 72 h postinfection, large multinucleated syncytia were observed in all tumor cells infected with ICOVIR16 (Figure 1c) . Tumor cell lines displayed differential sensitivity to GALV fusion induction. Although SKMel-28 and A549 cells infected with ICOVIR16 formed syncytia with an average of 30 nuclei, syncytia with more than 100 nuclei could be observed in NP18-infected cells. In contrast, non-treated tumor cells or tumor cells infected with control virus ICOVIR15 did not exhibit syncytia formation.
ICOVIR16 displays enhanced oncolytic potency in vitro
In agreement with our previous observations using the replication-competent adenovirus AdwtRGD --GALV, 28 the expression of GALV also enhanced the oncolytic potency of the oncolytic adenovirus ICOVIR16. The amount of ICOVIR16 required to reduce the cell culture viability by 50% (IC50) was 2.6 times and 2.8 times lower in SKMel-28 and NP-9 cells, respectively, compared with the parental virus ICOVIR15 (Figure 2 ). In both cases, the degree of tumor cell killing correlated with the extent of syncytia formation. Next, we confirmed the enhanced cytotoxicity of ICOVIR16 in carcinoma-associated fibroblasts (CAF) of human origin. CAF has been considered as a major barrier for efficient virus spread, and therefore, an oncolytic adenovirus capable of efficiently replicating in and eliminating CAF would be highly advantageous. Although both viruses efficiently eliminated CAF cells, the IC50 value of ICOVIR16 was 4.3 times lower than that of ICOVIR15, indicating that syncytia formation can increase the cytotoxicity of an oncolytic adenovirus in all tumor cell types analyzed. As CAF cultured in vitro and in the tumor context are induced to proliferate and therefore has an active E2F-pRB pathway, ICOVIR16 cytotoxicity in these cells was expected, but raises the question on the replication of ICOVIR16 in quiescent human normal cells. To answer this, we infected isolated human pancreatic islets in vitro with a wild-type RGD-modified fiber Ad5 or ICOVIR16 at 200 MOI. Two hours after infection, islets were washed with phosphatebuffered saline (PBS) and incubated in fresh virus-free medium. After washing, a small fraction of the SN was collected and the input virus was titrated by a-hexon staining (time 0). The results at day 0 (input background control) indicated a background virus level for both viruses of 5 Â 10e3 TU ml
À1
. At day 6, the titer of the wild-type virus had increased 100-fold compared with day 0. By contrast, we could not detect virus production in the pancreatic islets infected with ICOVIR16. The levels for wild-type virus and ICOVIR16 at day 6 were 4.7±1.5 Â 10e5 and 0.072±0.05 Â 10e5 TU ml À1 , respectively.
ICOVIR16 exhibits enhanced antitumoral efficacy following intratumoral administration in vivo.
To analyze whether the enhanced tumor cell killing displayed by ICOVIR16 in vitro would translate into an enhanced antitumor effect in vivo, mice bearing SkMel-28 tumors (average size of 130 mm 3 ) were treated with a single intratumoral injection of PBS, ICOVIR15 or ICOVIR16 (1 Â 10 9 viral particles/tumor). Tumor growth was monitored for 6 weeks post-injection. Tumor progression was significantly reduced by both ICOVIR15 (P ¼ 0.0132) and ICOVIR16 (P ¼ 0.000017) compared with PBS-treated tumors (Figure 3a) . Importantly, the GALV-expressing adenovirus, ICOVIR16, exhibited a vigorous antitumor efficacy, significantly greater than that of its nonfusogenic counterpart, ICOVIR15 (Pp0.04). Although only 20% of tumors treated with ICOVIR15 showed partial regressions at ICOVIR16 exhibits enhanced antitumoral efficacy following systemic administration in vivo Systemic administration is a requisite for the efficient therapy of metastatic cancer. Therefore, we next evaluated the ability of ICOVIR16 Figure 2 . GALV expression increases tumor cell killing of an oncolytic adenovirus. SkMel-28 and NP9 tumor cells and carcinoma-associated fibroblasts (CAF) were infected with ICOVIR15 or ICOVIR16 at different MOI or remained uninfected. At indicated time points, cells were collected, stained with trypan blue and counted. The amount of viral particles/cell that produced 50% growth inhibition (IC50 value) was estimated. to control tumor growth when administered intravenously (i.v.). Mice bearing SkMel-28 melanoma tumor xenografts (average size of 100 mm 3 ) were treated with a single dose of PBS, ICOVIR15 or ICOVIR16 at 5 Â 10 10 vp per mouse delivered via the tail vein. In this model, treatment with ICOVIR15 had a minimal effect on tumor growth, with most tumors continuing to grow in a similar pattern to those treated with PBS ( Figure 3c ). In contrast, treatment with ICOVIR16 resulted in a significant reduction in tumor growth when compared with both ICOVIR15 and PBS treatments from the start of the treatment (day 6) through the end of the study (day 49). Importantly, at the end of the experiment, complete tumor regression was observed in 20% of the tumors treated with ICOVIR16.
As fused cells die slower than infected cells, the growing rate of the tumor model could influence the therapeutic efficacy of a fusogenic virus. To verify that the antitumoral activity of ICOVIR16 is not restricted to slow-growing tumor models (as SKMel-28 tumors), we performed an additional study using a more aggressive, fast-growing model. Mice bearing NP18 tumors (average size of 60 mm 3 ) were treated with a single dose of PBS, ICOVIR15 or ICOVIR16 at 5 Â 10 10 vp/mouse administered via tail vein (Figure 3d ). The experiment was finished 30 days following treatment due to the large size of the tumors in the PBS-treated group. Compared with the PBS controls, a single injection of either ICOVIR15 or ICOVIR16 had an immediate effect on tumor growth. Of note, ICOVIR16 resulted in significant antitumoral efficacy when compared with its non-fusogenic counterpart, ICOVIR15, from the start of the treatment (day 3) through the end of the study (day 49). The robust therapeutic effect of ICOVIR16 after systemic administration using two different tumor xenografts highlights the benefits of arming an oncolytic adenovirus with GALV. Table 1 summarizes the in vivo results of ICOVIR16 therapy.
ICOVIR16 induced syncytia formation and displayed an enhanced intratumoral spread in vivo at late times after virus infusion. Next, we assessed the intratumoral viral spread and syncytia formation in vivo in SKMel-28 and NP18 tumor xenografts harvested at the end of the study. The presence of adenovirus progeny was analyzed by immunostaining for adenovirus late proteins in frozen tumor sections (Figure 4a) , and the percentage of stained areas was quantified in each tumor model (Figure 4b ). Tumors treated with ICOVIR16 showed broader areas of tumor replication when compared with tumors treated with ICOVIR15. Although the differences in virus spread were found to be statistically significant in the pancreatic tumor model (NP18), significance was not reached when using the melanoma tumor model (SKMel-28). Immunohistochemistry for adenovirus late proteins of the ICOVIR16-treated tumors demonstrated extensive syncytia formation, corresponding to the regions of virus replication (data not shown).
To further investigate the mechanisms underlying the enhanced antitumor efficacy showed by ICOVIR16, the experiment of Figure 3c was repeated, except that the tumors were harvested at early time points. In contrast to the results obtained at late times after treatment, virus was similarly detected in ICOVIR15-and ICOVIR16-treated tumors at day 8, 14 and 18 after treatment (Figure 4c) . In ICOVIR16-treated tumors, syncytia were frequently found near necrotic areas and surrounded by fibrotic tissue. No syncytia formation was observed in tumors treated with ICOVIR15 or PBS. Of note, tumors treated with ICOVIR16 showed wider areas of necrosis at all time points, compared with those treated with ICOVIR15. Finally, the amount of inflammatory cells (granulocytes, monocytes, lymphocytes) was evaluated by a trained pathologist (FV) in the same hematoxylin-counterstained tumor sections used to evaluate the presence of ICOVIR15 and ICOVIR16 at different time points (six tumors at days 8, 14 and 18; Figure 4c ). There was no differential inflammation observed in the tumor between the different treatment groups.
ICOVIR16 displays similar safety profile to ICOVIR15 after systemic administration in hamsters. Because mice are poorly permissive for human adenoviruses, and Syrian hamsters, which are Figures (3c and d) . PR was defined as a volume regression of 430%. A CR was defined as a disappearance of measurable tumor mass. Stable disease was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for progressive disease (up to 30% increase in volume). permissive for Ad5 replication, do not express the GALV receptor Pit-1, toxicology studies with ICOVIR16 are hampered by the lack of an appropriate animal model. However, as a first step towards evaluating the toxicity of ICOVIR16, we evaluated the potential side effects of the virus in Syrian hamsters. In a preliminary experiment, we injected the replication competent adenovirus AdwtRGD and this same virus treated with UVpsoralen (which eliminates virus replication and transcription) at high doses (4 Â 10 11 vp) into Syrian hamsters via the cephalic vein. Two days after virus injection, hamsters treated with AdwtRGD were killed due to lethal toxicity, characterized by extensive petechiae and a severe increase in liver transaminases (Figure 5a ). No petechiae were observed in hamsters injected with PBS or with the non-replicating particle control (AdwtRGD UV-psoralen). In a next experiment, hamsters received 4 Â 10 11 vp of ICOVIR15 or ICOVIR16 via the cephalic vein. Five days after viral injection, liver enzymes and hematological profile were determined. Both ICOVIR15 and ICOVIR16 viruses induced a modest increase in Aspartate transaminase (AST) and alanine transaminase (ALT) levels (Figure 5b ), a modest but significant decrease in platelets ( Figure 5c ) and a slight increase in neutrophils, basophils and monocytes (Figure 5e ), compared with the PBS-treated hamsters. Of note, animals treated with ICOVIR16 showed a significant increase in serum levels of liver enzymes compared with ICOVIR15, suggesting that GALV expression could be slightly toxic even in the absence of fusion induction. No petechiae were observed in hamsters treated with both selective replication adenoviruses.
DISCUSSION
Enhancing the efficacy of the current oncolytic adenoviruses represents one of the major challenges to obtaining clinical benefits in cancer patients. We have previously reported the generation of a replication-competent adenovirus expressing GALV, a fusogenic membrane glycoprotein highly cytotoxic for tumor cells. 28 This fusogenic adenovirus (AdwtRGD --GALV) induced massive syncytia formation and showed an enhanced cell killing in vitro. In this current study, we have demonstrated that expression of GALV by an oncolytic adenovirus (ICOVIR16) can induce syncytia formation in vivo, improve viral spread through the tumor mass and enhance the overall antitumoral efficacy, following both systemic or intratumoral administration.
Consistent with our earlier findings, 28 we demonstrated that GALV expression by an oncolytic adenovirus resulted in significantly increased cell killing. However, this increase in tumor cell killing was modest compared with the fusogenic activity of GALV. Although infection of SKMel-28 cells with ICOVIR16 induced the formation of syncytia with an average of 30 nuclei, ICOVIR16 was only 2.6-fold more cytotoxic than ICOVIR15 in this cell line. These results suggest that the cytotoxicity induced by ICOVIR16 in vitro correlates not only with the number of cells included in syncytia, but also with: (a) the amount of virus produced inside the syncytia, (b) the efficacy of virus release and (c) the rate of cell death. In the present study, we have demonstrated that ICOVIR16 is produced as efficiently as ICOVIR15 after infection at high MOI. However, we have previously shown that after infection at low MOI with the replication-competent fusogenic adenovirus AdwtRGD --GALV, the formation of large multinucleated syncytia impairs virus production and decreases the amount of virus released to the SN. 28 Moreover, syncytia formed at low MOI remain viable for a long time, dying approximately around day 4 or 5 post-infection. Therefore, one might reasonably expect that ICOVIR16 cytotoxicity could be increased when GALV expression is combined with strategies directed to enhance the rate of adenovirus release and cell death. In this regard, we have previously demonstrated that a C-terminal mutation in the E3/19K protein enhances the release of adenovirus from the infected cell and improves its antitumoral efficacy. 30 Also, in a previous work, we demonstrated that the calcium channel blocker verapamil can improve the rate of adenovirus release and spread, enhancing the therapeutic activity of oncolytic adenoviruses. 6 We are currently analyzing whether the combination of these strategies with the expression of GALV will further enhance the antitumoral efficacy of the fusogenic adenovirus.
Consistent with the enhanced tumor cell killing shown in vitro, administration of ICOVIR16 into large tumor xenografts was also more efficient than the non-fusogenic adenovirus (ICOVIR15) at controlling tumor growth. Importantly, a single administration of ICOVIR16 either intratumorally or systemically was enough to induce a strong and sustained antitumoral response that was visible shortly after virus injection. Moreover, GALV expression enhanced adenovirus spread throughout the tumor mass. However, this enhanced spread was only found to be statistically significant in one of the two in vivo models (NP18), and although almost all tumors showed active ICOVIR16 replication areas, complete tumor responses were rarely achieved. One possible explanation is that the extensive necrotic areas and fibrotic changes occurring around regions of viral replication act as physical barriers hampering adenovirus spread throughout the tumor. However, it is important to note that in a xenograft model, the tumor stroma is of mouse origin, and therefore, it is difficult to eliminate, as mouse cells are not permissive to adenovirus replication and do not express fusion-competent receptors for GALV. In contrast, we demonstrate here that ICOVIR16 efficiently eliminates CAF of human origin. These results suggest that, in human patients, ICOVIR16 should spread even more efficiently than ICOVIR15, as it is able to replicate in tumor-associated fibroblasts and induce their fusion.
One further advantage of expressing GALV from an oncolytic adenovirus is that syncytial cell death is highly immunogenic. 21 Fusion of tumor cells results in the release of large numbers of tumor-derived, exosome-like vesicles, which are associated with an effective release of tumor antigens, their efficient transfer into immature dendritic cells, and subsequent cross-presentation to T cells to generate systemic antitumor immune responses. 22, 31 Therefore, ICOVIR16-mediated oncolysis may combine very effective local effects with the potential to induce antitumor immunity. However, in the present work, we could not address the immunotherapeutic potential of our virus due to limitations in the tumor models. First, in vivo experiments were performed in human xenografts in nude mice, as mouse cells are not permissive for human adenovirus replication. Second, cell-to-cell fusion with GALV requires expression of the Pit-1 receptor, which is not present in rodent cells. Recently, the Syrian golden hamster has been suggested as a permissive animal for adenoviral replication. 32, 33 Although this model offers the opportunity to evaluate the effect of oncolytic adenoviruses in an immunocompetent animal, hamster cells do not express fusion-competent receptors for GALV. A transgenic Pit-1 animal model permissive to human adenovirus replication would be required to test the immunogenicity of the syncytia induced by ICOVIR16.
One major concern regarding the insertion of the GALV gene into an oncolytic adenovirus was that the resulting genome would exceed the accepted packaging limit size of the adenovirus genome size (105%), resulting in genome instability and packaging problems. 34 As a first approach, we expressed GALV from ICOVIR5, 35 an oncolytic adenovirus highly selective for tumor cells, but with a genome size approaching the packaging limit. To accommodate the insertion of the GALV gene without affecting the packaging, the E4orf1, E4orf2 and E4orf3 genes were deleted from the resulting fusogenic adenovirus (SG, unpublished results).
Although deletion of these genes in Adwt mutants has no detrimental effect on viral replication, 36 our resulting fusogenic adenovirus showed severe defects in viral replication and packaging. We did not consider the deletion of other viral regions, such as the E3 region or the E1b-55k gene, as previous studies have indicated that they can have detrimental effects on oncolytic potency. 37 --39 Importantly, insertion of the GALV gene in ICOVIR15 did not require the deletion of any viral gene. The ICOVIR16 genome tolerated a net increase in viral DNA of B2.2 kb, without any detectable sign of genome instability or packaging defects. Moreover, our in vitro studies showed that the replication efficiency of this virus was not compromised by the insertion of the GALV gene.
Finally, another important issue that may be considered is that GALV expression could increase the toxicity of the oncolytic virotherapy. In this work, we sought to prevent the uncontrolled induction of syncytia formation in normal tissue by expressing GALV late in the adenoviral infection cycle, under the control of the major late promoter. Late GALV expression by an oncolytic adenovirus should only occur in tumor cells, thus retaining the safety of the original virus in normal cells. In our in vivo efficacy studies in immunodeficient mice, we did not detect a significant change in animal weight or activity following i.v. injection of ICOVIR16 compared with ICOVIR15. However, when administered in hamsters, an immunocompetent model permissive for adenovirus replication, ICOVIR16 induced a higher increase in liver transaminases than that induced by ICOVIR15. Taking into account that GALV expression does not induce fusion in hamster cells, this increased toxicity could be due to the immunogenic nature of the GALV protein. Before ICOVIR16 can be considered for use as a cancer therapy, further biodistribution and toxicity studies must be conducted to establish the safety profile of the virus.
In summary, our results demonstrate that GALV expression enhances the intratumoral spread and the antitumor activity of the oncolytic adenovirus ICOVIR16. Also, we show that ICOVIR16 has significant therapeutic potential against different tumors following both local and systemic administration, resulting in tumor regression. However, due to the potential toxicity induced by GALV expression, and due to the unavailability of a suitable animal model, appropriate clinical trials are essential to analyze the safety profile of ICOVIR16 in the context of both local and systemic viral delivery.
MATERIALS AND METHODS
Cell culture HEK293, A549 lung adenocarcinoma cells and SkMel-28 melanoma cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). NP9 and NP18 pancreatic tumor cells were established in our laboratory. 40 Human CAF1 were isolated and characterized in our laboratory from hepatic metastases of a human colorectal carcinoma. All cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, with exception of CAF1 cells, which were maintained in Dulbecco's modified Eagle's medium-F12 supplemented with 10% fetal bovine serum and BDMITO þ serum extender (Becton Dickinson, Erembodegem, Belgium).
Pancreatic islets were kindly provided by Dr Montanya of the Endocrinology Service of the Hospital de Bellvitge, Barcelona, Spain. Isolated islets were seeded in triplicate in 24-well plates (6 islets per well) and infected with RGD-capsid modified wild-type virus or ICOVIR16 at 200 MOI (assuming 1000 cells per islet). Two hours after infection, islets were washed three times with PBS and incubated in fresh virus-free medium. After washing, a small fraction of the SN was collected and the input virus was titrated by a-hexon staining (time 0 or non-rinsed background level). At day 6 after infection, the islets and the medium were harvested and freeze-thawed three times to obtain the cell extract. Infectious units virus titer was determined by a-hexon staining.
Recombinant adenoviruses AdwtRGD has been previously described. 35 To obtain the non-replicating particle control, AdwtRGD UV-psoralen, the AdwtRGD was inactivated by UV-psoralen as previously described. 41 ICOVIR15 is a conditionally replicating adenovirus in which expression of the adenovirus E1A-D24 gene is regulated by a modified endogenous E1A promoter, which contains eight E2F-1-binding sites and one Sp1-binding site. To generate ICOVIR16, a shuttle plasmid, pNKFiberGALV, was constructed as follows. cDNA corresponding to the hyperfusogenic GALV envelope was amplified by PCR, using pCR3.1 --GALV as the template DNA. 27 GALV cDNA contains a PacI site at position 1588, which was eliminated by PCR mutagenesis, using a two-step procedure. In the first step, two separate PCRs were used to generate the primary PCR products, which contained the Pac I mutation, as well as overlapping regions. In the second step, the PCR products were mixed and re-amplified with specific primers engineered to amplify the complete GALV cDNA. The forward primer contained the acceptor splicing sequence of the virus protein IIIa and the Kozak sequence, and the reverse primer contained a polyadenylation signal for GALV. Both primers contained EcoR I restriction sites. The PCR product, containing the GALV cassette, was digested with EcoR I and ligated to the pNKFiberRGD plasmid 19 to generate pNKFiberGALV. The Not I-Kpn I fragment of pNKFiberGALV and the partially Swa I digested pVK50cau 12 were recombined by homologous recombination, performed in yeast. This recombination event resulted in generation of the pAdwtRGD --GALV. pICOVIR16 was obtained using a similar strategy; pICOVIR15 was partially digested with Spe I and recombined with the Spe I-Pac I fragment of pAdwtRGD --GALV. ICOVIR16 was generated in HEK293 and plaque-purified in A549 cells. Both viruses were amplified in A549 cells, purified on CsCl gradients according to standard techniques and quantified using the antihexon staining-based method using 293 cells. 30 Production assays A549 cells were infected with 25 TU per cell of each virus to allow for 80% to 100% infection. Four hours later, infection medium was removed; cells were washed twice with PBS and incubated with fresh medium. After 48 and 72 h, cells with medium were harvested and subjected to three rounds of freeze-thaw lysis (cell extract 'CE'). To quantify the virus released into the medium, a small fraction of the SN was also removed for analysis before harvesting the cells. Viral titers of SN and CE were determined in triplicate according to an anti-hexon staining-based method in HEK293 cells. 30 In vitro cytotoxicity assay Cytotoxicity assay was performed by seeding 10 000 SkMel-28, NP9 and CAF cells in 96-well plates in Dulbecco's modified Eagle's medium with 5% fetal bovine serum. Cells were infected with 1/3 serial dilutions of purified virus, starting with 180 TU per cell for SkMel-28 and NP9, and 200 TU per cell for CAF. At the indicated time points, cells were collected, stained with trypan blue and counted. The percentage of cell viability was determined by dividing the number of viable cells from the infected wells by the number of cells from uninfected wells. IC50 value was calculated from dose-response curves by standard non-linear regression (GraFit; Erithacus Software, Horley, UK) using an adapted Hill equation.
In vivo viral distribution study 
In vivo efficacy studies
To evaluate the intratumoral efficacy of the fusogenic adenovirus ICOVIR16, mice bearing established SkMel-28 tumors (130 mm 3 ) received a single intratumoral injection of PBS or 1 Â 10 9 viral particles of each virus (n ¼ 10). To evaluate systemic efficacy, subcutaneous SkMel-28 melanoma or NP18 pancreatic tumors were established by injection of 5 Â 10 6 cells into the flanks of 6-week-old male Balb/C nu/nu mice. Once tumors reached the desired mean tumor volume (100 mm 3 for SkMel-28 and 60 mm 3 for NP18 tumors), mice were randomly distributed into treatment groups (n ¼ 10 tumors per group) and treated with a single i.v. injection of PBS or 5 Â 10 10 vp of ICOVIR15 or ICOVIR16 given via tail vein. In all animal experiments, tumor progression and morbidity status were monitored three times weekly. Tumor volume and percentage of tumor growth were calculated as previously described. The two-tailed Student's t-test was used to compare the differences in tumor volume and tumor progression in mice for each cohort.
At the end of the study, animals from each group were euthanized and tumors were collected, weighted and cut into halves. One half was frozen in OCT and the other half was fixed in 4% formaldehyde for 24 h and embedded in paraffin.
Immunohistochemistry
Immunofluorescence for adenovirus late protein expression was performed on OCT-embedded tumor sections, as previously described. 35, 42 Images of sections were obtained on an Olympus BX60 fluorescence microscope. (Olympus, Tokyo, Japan). To quantify adenovirus-positive replication areas, five random fields in viable tissue zones for each tumor were captured at Â 100 magnification. Taking five fields per tumor, we could capture all or most of the viable tissue for each tumor. Quantification of percentage of stained areas was done using ImageJ (NIH) software by analyzing the percentage of hexon-expressing area versus the total viable tissue. Necrotic areas were excluded. For immunohistochemical analysis, paraffin-embedded sections of SKMel-28 tumors were treated with an antiadenovirus antibody (Ab6982; Abcam, Cambrige, UK) or with anti-E1A antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunohistochemical staining was performed with EnVision (DAKO, Hamburg, Germany), according to the manufacturer's instructions.
In vivo toxicity studies
Five-week-old, female, immune-competent Syrian (golden) hamsters (Mesocricetus auratus) were used. A single dose of 4Â 10 11 vp of AdwtRGD, AdwtRGD UV-psoralen, ICOVIR15 or ICOVIR16 was administered i.v. into the cephalic vein on day 0 in a volume of 300 ml of PBS. The control group was injected with an equal volume of PBS. Animals were examined daily for clinical signs of toxicity. At indicated time points, hamsters were killed, and whole blood and serum samples were collected through cardiac puncture. Clinical biochemistry of transaminases levels and hematological determinations were performed by the Clinical Biochemistry and Hematological Services of the Veterinary Faculty at the Autonomous University of Barcelona.
